These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 30624128

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK, Schröder FH.
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [Abstract] [Full Text] [Related]

  • 3. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer.
    Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE.
    J Urol; 2011 Sep; 186(3):889-97. PubMed ID: 21788033
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
    Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A, Persson BE.
    Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer.
    de la Rosette J, Davis R, Frankel D, Kold Olesen T.
    Int J Clin Pract; 2011 May; 65(5):559-66. PubMed ID: 21342376
    [Abstract] [Full Text] [Related]

  • 8. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
    Lee D, Porter J, Gladwell D, Brereton N, Nielsen SK.
    J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
    [Abstract] [Full Text] [Related]

  • 9. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K, Sasaki H, Kido M, Takahashi H, Aoki M, Egawa S.
    BMC Cancer; 2016 Sep 01; 16(1):708. PubMed ID: 27586506
    [Abstract] [Full Text] [Related]

  • 10. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists.
    Van Poppel H, Klotz L.
    Int J Urol; 2012 Jul 01; 19(7):594-601. PubMed ID: 22416801
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
    Anderson D, Lehmann J, Ecker T, Vosgerau S, Donatz V.
    Urologe A; 2017 Jul 01; 56(7):917-924. PubMed ID: 28405705
    [Abstract] [Full Text] [Related]

  • 14. Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer.
    Steinberg M.
    Clin Ther; 2009 Jul 01; 31 Pt 2():2312-31. PubMed ID: 20110043
    [Abstract] [Full Text] [Related]

  • 15. Degarelix.
    Frampton JE, Lyseng-Williamson KA.
    Drugs; 2009 Oct 01; 69(14):1967-76. PubMed ID: 19747011
    [Abstract] [Full Text] [Related]

  • 16. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
    Sasaki H, Miki K, Tashiro K, Mori K, Urabe F, Fukuokaya W, Kimura T, Sato S, Takahashi H, Aoki M, Egawa S.
    Andrology; 2022 Feb 01; 10(2):270-278. PubMed ID: 34510814
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
    Klotz L.
    Expert Opin Drug Metab Toxicol; 2015 Feb 01; 11(11):1795-802. PubMed ID: 26513436
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.